↓ Skip to main content

Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control

Overview of attention for book
Attention for Chapter 12: Evolution of Phenotypic and Molecular Drug Susceptibility Testing
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
66 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Evolution of Phenotypic and Molecular Drug Susceptibility Testing
Chapter number 12
Book title
Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-3-319-64371-7_12
Pubmed ID
Book ISBNs
978-3-31-964369-4, 978-3-31-964371-7
Authors

Daniela M. Cirillo, Paolo Miotto, Enrico Tortoli, Cirillo, Daniela M., Miotto, Paolo, Tortoli, Enrico

Abstract

Drug Resistant Tuberculosis (DRTB) is an emerging problem world-wide. In order to control the disease and decrease the number of cases overtime a prompt diagnosis followed by an appropriate treatment should be provided to patients. Phenotypic DST based on liquid automated culture has greatly reduced the time needed to generate reliable data but has the drawback to be expensive and prone to contamination in the absence of appropriate infrastructures. In the past 10 years molecular biology tools have been developed. Those tools target the main mutations responsible for DRTB and are now globally accessible in term of cost and infrastructures needed for the implementation. The dissemination of the Xpert MTB/rif has radically increased the capacity to perform the detection of rifampicin resistant TB cases. One of the main challenges for the large scale implementation of molecular based tests is the emergence of conflicting results between phenotypic and genotypic tests. This mines the confidence of clinicians in the molecular tests and delays the initiation of an appropriate treatment. A new technique is revolutionizing the genotypic approach to DST: the WGS by Next-Generation Sequencing technologies. This methodology promises to become the solution for a rapid access to universal DST, able indeed to overcome the limitations of the current phenotypic and genotypic assays. Today the use of the generated information is still challenging in decentralized facilities due to the lack of automation for sample processing and standardization in the analysis.The growing knowledge of the molecular mechanisms at the basis of drug resistance and the introduction of high-performing user-friendly tools at peripheral level should allow the very much needed accurate diagnosis of DRTB in the near future.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 66 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 14%
Other 9 14%
Student > Bachelor 8 12%
Student > Master 7 11%
Student > Ph. D. Student 6 9%
Other 8 12%
Unknown 19 29%
Readers by discipline Count As %
Immunology and Microbiology 11 17%
Medicine and Dentistry 10 15%
Biochemistry, Genetics and Molecular Biology 7 11%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Mathematics 3 5%
Other 9 14%
Unknown 22 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2018.
All research outputs
#15,483,026
of 23,007,887 outputs
Outputs from Advances in experimental medicine and biology
#2,514
of 4,961 outputs
Outputs of similar age
#257,358
of 421,256 outputs
Outputs of similar age from Advances in experimental medicine and biology
#235
of 490 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,961 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,256 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 490 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.